Angeline S. Andrew, Ph.D.
Department(s):
Community and Family Medicine
Title:
Assistant Professor of Community and Family Medicine
Education:
Dartmouth Medical School, PhD 2001
Tufts University, BS 1996
Programs:
Norris Cotton Cancer Center
Websites:
www.dartmouth.edu/~toxmetal/RSCR.shtml
Contact Information:
7927 Rubin Building,
Room 860
Dartmouth Medical School
One Medical Center Drive
Lebanon, NH 03756
Phone: 603-653-9019
Fax: 603-653-9093
Email: Angeline.Andrew@dartmouth.edu
Selected Recent Publications:
Andrew AS, Warren AJ, Barchowsky A, Temple KA, Klei L, Soucy NV, O¹Hara KA, Hamilton JW. Genomic and proteomic profiling responses to heavy metals in human lung cells. Environmental Health Perspectives - Toxicogenomics 2003; 111(6): 825-838.
Andrew AS, Heaney J, Schned A, and Karagas MR. Bladder cancer risk and personal hair dye use in women. Int J Cancer 2004; 109(4): 581-586.
Kelsey KT, Hirao T, Schned A, Hirao S, Devi-Ashok T, Nelson H, Andrew AS, Karagas MK. A Population-based Study of Immunohistochemical detection of p53 Alteration in Bladder Cancer. Br J Cancer 2004; 90(8):1572-1576.
Karagas MR, Park S, Nelson HH, Andrew AS, Mott L, Schned A, et al. Methylenetetrahydrofolate reductase (MTHFR) variants and bladder cancer: a population-based case-control study. Int J Hyg Environ Health 2005; 208:321-327.
Marsit CJ, Karagas MR, Andrew AS, Liu M, Danaee H, Schned AR, Nelson HH, Kelsey KT. Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer. Cancer Research 2005; 60(16):7081-7085.
Hirao S, Kelsey KT, Hirao T, Schned AR, Ashok T, Nelson HH, Andrew AS, Karagas MR. Loss of Heterozygosity on Chromosome 9q and p53 Alterations in Human Bladder Cancer. Cancer 2005; 104(9): 1918-1923.
Kelsey KT, Hirao T, Hirao S, Devi-Ashok T, Nelson HH, Andrew AS, Colt J, Baris D, Morris SJ, Schned AR, Karagas MR. TP53 alterations and patterns of carcinogen exposure in a US population-based study of bladder cancer. Intl. J. Cancer 2005; 117(3):370-375.
Andrew AS, Nelson HH, Kelsey KT, Moore JH, Meng, AC, Casella DP, Tosteson T, Schned AR, Karagas MR. Concordance of Multiple Analytical Approaches Demonstrates a Complex Relationship Between DNA Repair Gene SNPs, Smoking, and Bladder Cancer Susceptibility. Carcinogenesis 2006; 27(5): 1030-1037.
Karagas MR, Nelson HH, Sehr P, Waterboer T, Stukel TA, Andrew A, et al. Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin. J Natl Cancer Inst 2006;98(6):389-395.
Marsit CJ, Karagas MR, Danaee H, Liu M, Andrew AS, Schned A, Nelson HH Kelsey KT. Carcinogen exposure and gene promoter hypermethylation in bladder cancer. Carcinogenesis 2006; 27:112-6.
Andrew AS, Burgess JL, Meza MM, Demidenko E, Waugh MG, Hamilton JW, Karagas MR. Arsenic Exposure is Associated with Decreased DNA Repair In Vitro and in Individuals Exposed to Drinking Water Arsenic. Environ. Health Perspectives 2006; 114:1193-1198.
Karagas MR, Zens MS, Nelson HH, Mabuchi K, Perry AE, Stukel TA, Mott LA, Andrew AS, Applebaum KM, Linet M. Measures of cumulative exposure from a standardized sun exposure history questionnaire: a comparison with histologic assessment of solar skin damage. Am J Epidemiol. 2007 165:719-26.
Andrew AS, Karagas MR, Guarrera S, Nelson HH, Sacerdote C, Polidoro S, Gamberini S, Moore JH, Kelsey KT, Demidenko E, Vineis P, Matullo G. DNA Repair Polymorphisms Modify Bladder Cancer Risk: A Multi-factor Analytic Strategy. (Human Heredity in press)
Andrew AS, Bernardo V, Davey J, Inhat MA, Warnke LA, Waugh M, Hampton T, Davey JC, Hamilton J. Exposure to Arsenic in Drinking Water at U.S. Levels Modifies Gene Expression in the Mouse Lung (Tox. Sci. in press).
Schned AR, Andrew AS, Marsit C, Zens MS, Kelsey KT, Karagas MR. Survival following the diagnosis of non-invasive bladder cancer: WHP/ISUP vs. WHO classification systems. (J. Urology in press)
Fortuny J, Kogevinas M, Zens MS, Schned A, Andrew AS, Heaney J, Karagas MR. Bladder cancer risk and use of analgesic and anti-inflammatory drugs. A population-based case-control study. BMC Urol. 2007 7:13.
Research Interests:
Dr. Andrew's research program focuses on understanding mechanisms by which the toxic metal arsenic causes cancer and impact prognosis. Drinking water arsenic exposure occurs in rural areas of NH due to geologic contamination of unregulated private wells. Dr. Andrew has several projects that aim to elucidate the mechanism of lung and bladder carcinogenesis.
Dr. Andrew has shown that arsenic inhibits expression of DNA repair genes, including ERCC1. She demonstrated a functional decrease in DNA repair capacity in arsenic exposed cells in culture and using ex-vivo lymphocyte samples from arsenic-exposed individuals.
Inspired by the clinical observations from the Dmitrovsky lab, the Andrew group recently observed that the lung carcinogen, arsenic activates the Epidermal Growth Factor Receptor (EGFR) in human lung epithelial cells. Dr. Andrew is currently investigating the mechanisms of this activation and its downstream signaling implications in cell culture. Assisted by NCCC developmental funds in collaboration with Dr. Memoli and the Research Pathology shared resource, they have constructed a lung tumor microarray that has allowed them to translate these findings into human tissues by correlating immunohistochemical staining with arsenic exposure levels.
Using the Microarray and Bioinformatics shared resources, Dr. Andrew has taken a toxicogenomic approach to investigate the impact of arsenic exposure on gene expression. She observed an immunosuppressive effect of arsenic in the lungs of arsenic-exposed mice and in the lymphocytes of New Hampshire residents exposed to arsenic in their drinking water. She plans to investigate the functional effect of arsenic on immune response with assistance from the Immune Monitoring lab.
Dr. Andrew is also conducting a comprehensive analysis to understand the origin of somatic alterations in a histologically selected set of lung tumors by overlaying epidemiologic data (gender, smoking status, occupation, toenail metal levels) with full-spectrum alteration analyses: DNA - chromosome insertion/deletions, mutation data; RNA gene expression levels; protein immunohistochemical staining. This project takes full advantage of the cancer center resources, including CGH arrays from the Microarray shared resource, sequencing by the Molecular Biology shared resource, immunohistochemical staining by the Research Pathology shared resource, and analysis assistance through Biostatistics.
Courses Taught:
Lecturer, Pharm 126 Cancer Biology;
Lecturer, Pharm 123 Graduate Toxicology
Lecturer, Pharm 122 Current Approaches in Experimental Therapeutics;
Small group leader, DMS Epidemiology and Biostatistics.
Grant Information:
- 1K07CA102327 Angeline Andrew (PI) 9/1/05 - 8/31/10
NIH/NCI Bladder Cancer Prognostic Indicators
- 5 P42 ES07373 (Hamilton) 4/1/05 – 3/31/08 NIH/NIEHS Toxic Metals in the Northeast: From Biological to Environmental Implications. Co-PI Project 4: Arsenic epidemiology, biomarkers and exposure assessment. PI Core D: Biomarkers Core.
- P20 RR-018787-01 (Stanton) 10/01/03 - 09/30/08
NIH-NCRR Cellular and Molecular Mechanisms of Lung Disease - COBRE. Co-Investigator Project 5: Environmental Epidemiology of Lung Cancer in New Hampshire.
- R03CA121382 Angeline Andrew (PI) 4/1/06 - 3/31/08 NIH/NCI Comprehensive Assessment of Bladder Cancer Genetic Susceptibility
|
